• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

效应细胞因子的独特特征标志着克罗恩病的不同阶段。

Distinct profiles of effector cytokines mark the different phases of Crohn's disease.

机构信息

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

出版信息

PLoS One. 2013;8(1):e54562. doi: 10.1371/journal.pone.0054562. Epub 2013 Jan 17.

DOI:10.1371/journal.pone.0054562
PMID:23349929
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3547873/
Abstract

OBJECTIVE

Crohn's Disease (CD)-associated inflammation is supposed to be driven by T helper (Th)1/Th17 cell-derived cytokines, even though there is evidence that the mucosal profile of cytokine may vary with the evolution of the disease. We aimed at comparing the pattern of effector cytokines in early and established lesions of CD.

DESIGN

Mucosal samples were taken from the neo-terminal ileum of CD patients undergoing ileocolonic resection, with (early lesions) or without post-operative recurrence, and terminal ileum of CD patients with long-standing disease undergoing intestinal resection (established lesions). Inflammatory cell infiltrate was examined by immunofluorescence and cytokine expression was analysed by real-time PCR, flow-cytometry and ELISA.

RESULTS

Before the appearance of endoscopic lesions, the mucosa of the neo-terminal ileum contained high number of T cells and macrophages, elevated levels of Th1-related cytokines and TNF-α and slightly increased IL-17A expression. Transition from this stage to endoscopic recurrence was marked by abundance of Th1 cytokines, marked increase in IL-17A, and induction of IL-6 and IL-23, two cytokines involved in the control of Th17 cell responses. In samples with established lesions, there was a mixed Th1/Th17 response with no TNF-α induction. Expression of IL-4 and IL-5 was up-regulated in both early and established lesions even though the fraction of IL-4-producing cells was lower than that of cells producing either interferon-γ or IL-17A.

CONCLUSIONS

Distinct mucosal profiles of cytokines are produced during the different phases of CD. A better understanding of the cytokines temporally regulated in CD tissue could help optimize therapeutic interventions in CD.

摘要

目的

克罗恩病(CD)相关炎症被认为是由辅助性 T 细胞(Th)1/Th17 细胞衍生的细胞因子驱动的,尽管有证据表明黏膜细胞因子的特征可能随疾病的进展而变化。我们旨在比较 CD 的早期和已建立病变中效应细胞因子的模式。

设计

从接受回肠结肠切除术的 CD 患者的新末端回肠中采集黏膜样本,伴有(早期病变)或不伴有术后复发,以及患有长期疾病的 CD 患者的末端回肠行肠切除术(已建立病变)。通过免疫荧光检查炎症细胞浸润,通过实时 PCR、流式细胞术和 ELISA 分析细胞因子表达。

结果

在出现内镜病变之前,新末端回肠的黏膜含有大量 T 细胞和巨噬细胞,Th1 相关细胞因子和 TNF-α水平升高,IL-17A 表达略有增加。从这个阶段到内镜复发的转变以 Th1 细胞因子丰富为特征,IL-17A 显著增加,并诱导 IL-6 和 IL-23,这两种细胞因子参与控制 Th17 细胞反应。在已建立病变的样本中,存在混合的 Th1/Th17 反应,没有 TNF-α诱导。IL-4 和 IL-5 的表达在早期和已建立的病变中均上调,尽管产生 IL-4 的细胞比例低于产生干扰素-γ或 IL-17A 的细胞比例。

结论

在 CD 的不同阶段产生了不同的细胞因子黏膜谱。更好地了解 CD 组织中随时间调节的细胞因子可能有助于优化 CD 的治疗干预。

相似文献

1
Distinct profiles of effector cytokines mark the different phases of Crohn's disease.效应细胞因子的独特特征标志着克罗恩病的不同阶段。
PLoS One. 2013;8(1):e54562. doi: 10.1371/journal.pone.0054562. Epub 2013 Jan 17.
2
Compartmentalized expression of Th1 and Th17 cytokines in pediatric inflammatory bowel diseases.Th1 和 Th17 细胞因子在小儿炎症性肠病中的分隔表达。
Inflamm Bowel Dis. 2012 Jul;18(7):1260-6. doi: 10.1002/ibd.21905. Epub 2011 Oct 12.
3
Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease.克罗恩病早期及慢性回肠病变中不同的细胞因子模式。
Gastroenterology. 1997 Jul;113(1):118-26. doi: 10.1016/s0016-5085(97)70116-1.
4
TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation.TH1 和 TH17 细胞在炎症性肠病未治疗的炎症黏膜中的相互作用,及其介导炎症的潜力。
Cytokine. 2011 Dec;56(3):633-40. doi: 10.1016/j.cyto.2011.08.036. Epub 2011 Sep 25.
5
TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn's disease.固有层巨噬细胞产生的 TL1A 与 IL-23 协同作用,诱导克罗恩病患者产生 Th1 和 Th17 免疫应答。
Inflamm Bowel Dis. 2010 Apr;16(4):568-75. doi: 10.1002/ibd.21124.
6
High Smad7 in the early post-operative recurrence of Crohn's disease.Smad7水平升高与克罗恩病术后早期复发有关。
J Transl Med. 2020 Oct 19;18(1):395. doi: 10.1186/s12967-020-02558-8.
7
Increased Th17-inducing activity of CD14+ CD163 low myeloid cells in intestinal lamina propria of patients with Crohn's disease.克罗恩病患者肠道固有层中 CD14+CD163low 髓系细胞诱导 Th17 活性增强。
Gastroenterology. 2013 Dec;145(6):1380-91.e1. doi: 10.1053/j.gastro.2013.08.049. Epub 2013 Aug 29.
8
Increased fecal calprotectin levels in Crohn's disease correlate with elevated serum Th1- and Th17-associated cytokines.克罗恩病患者粪便钙卫蛋白水平升高与血清 Th1 和 Th17 相关细胞因子升高相关。
PLoS One. 2018 Feb 21;13(2):e0193202. doi: 10.1371/journal.pone.0193202. eCollection 2018.
9
Pathogenicity of In Vivo Generated Intestinal Th17 Lymphocytes is IFNγ Dependent.体内生成的肠道 Th17 淋巴细胞的致病性依赖于 IFNγ。
J Crohns Colitis. 2018 Jul 30;12(8):981-992. doi: 10.1093/ecco-jcc/jjy051.
10
Profiles of Lamina Propria T Helper Cell Subsets Discriminate Between Ulcerative Colitis and Crohn's Disease.固有层辅助性T细胞亚群特征可区分溃疡性结肠炎和克罗恩病。
Inflamm Bowel Dis. 2016 Aug;22(8):1779-92. doi: 10.1097/MIB.0000000000000811.

引用本文的文献

1
Optimizing Biologic Therapy for the Prevention of Post-Operative Recurrence in Crohn's Disease: Current Evidence and Future Perspectives.优化生物疗法预防克罗恩病术后复发:当前证据与未来展望
Biomedicines. 2025 May 19;13(5):1232. doi: 10.3390/biomedicines13051232.
2
Targeting CD4+ T cells through gut microbiota: therapeutic potential of traditional Chinese medicine in inflammatory bowel disease.通过肠道微生物群靶向CD4+ T细胞:中药在炎症性肠病中的治疗潜力
Front Cell Infect Microbiol. 2025 Mar 3;15:1557331. doi: 10.3389/fcimb.2025.1557331. eCollection 2025.
3
Immunohistochemistry Analysis in Inflammatory Bowel Disease-Should We Bring to Light Interleukin-10?

本文引用的文献

1
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.司库奇尤单抗,一种人源抗白细胞介素-17A 单克隆抗体,用于中重度克罗恩病:一项随机、双盲、安慰剂对照试验的意外结果。
Gut. 2012 Dec;61(12):1693-700. doi: 10.1136/gutjnl-2011-301668. Epub 2012 May 17.
2
Th17-cytokine blockers as a new approach for treating inflammatory bowel disease.Th17 细胞因子抑制剂作为治疗炎症性肠病的新方法。
Ann Med. 2011 May;43(3):172-8. doi: 10.3109/07853890.2010.531758. Epub 2010 Nov 30.
3
T-cell-directed therapies in inflammatory bowel diseases.
炎症性肠病中的免疫组织化学分析——我们应该揭示白细胞介素-10吗?
Biomedicines. 2025 Feb 7;13(2):406. doi: 10.3390/biomedicines13020406.
4
Multi-Omics Biomarkers for Predicting Efficacy of Biologic and Small-Molecule Therapies in Adults With Inflammatory Bowel Disease: A Systematic Review.用于预测生物制剂和小分子疗法对成人炎症性肠病疗效的多组学生物标志物:一项系统评价
United European Gastroenterol J. 2025 May;13(4):517-530. doi: 10.1002/ueg2.12720. Epub 2024 Dec 10.
5
Comparing the Effects of Anti-TNF Agent and Ustekinumab on Small Bowel Inflammation in Crohn's Disease: Inverse Probability Weighting With Stabilized Weights of Propensity Scores.比较抗TNF药物与优特克单抗对克罗恩病小肠炎症的影响:倾向得分稳定权重的逆概率加权法
Crohns Colitis 360. 2024 May 14;6(2):otae033. doi: 10.1093/crocol/otae033. eCollection 2024 Apr.
6
Management of Post-Operative Crohn's Disease: Knowns and Unknowns.术后克罗恩病的管理:已知与未知
J Clin Med. 2024 Apr 16;13(8):2300. doi: 10.3390/jcm13082300.
7
CD4 T-Cell Subsets and the Pathophysiology of Inflammatory Bowel Disease.CD4 T 细胞亚群与炎症性肠病的病理生理学。
Int J Mol Sci. 2023 Jan 31;24(3):2696. doi: 10.3390/ijms24032696.
8
A scoping review on early inflammatory bowel disease: definitions, pathogenesis, and impact on clinical outcomes.早期炎症性肠病的范围综述:定义、发病机制及对临床结局的影响
Therap Adv Gastroenterol. 2022 Dec 19;15:17562848221142673. doi: 10.1177/17562848221142673. eCollection 2022.
9
Intra-abdominal septic complications after ileocolic resection increases risk for endoscopic and surgical postoperative Crohn's disease recurrence.回肠结肠切除术后腹腔内化脓性并发症增加内镜和手术治疗后克罗恩病复发的风险。
J Crohns Colitis. 2022 Nov 23;16(11):1696-1705. doi: 10.1093/ecco-jcc/jjac078.
10
IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality.抗 TNF 治疗抵抗的 IBD 中 IL-23 阻断:从机制到临床现实。
J Crohns Colitis. 2022 May 11;16(Supplement_2):ii54-ii63. doi: 10.1093/ecco-jcc/jjac007.
T 细胞靶向治疗在炎症性肠病中的应用。
Clin Sci (Lond). 2010 Mar 30;118(12):707-15. doi: 10.1042/CS20100027.
4
IL-23/IL-17 axis in IBD.IL-23/IL-17 轴在 IBD 中的作用。
Inflamm Bowel Dis. 2010 Oct;16(10):1808-13. doi: 10.1002/ibd.21248.
5
Inflammatory bowel disease.炎症性肠病。
Annu Rev Immunol. 2010;28:573-621. doi: 10.1146/annurev-immunol-030409-101225.
6
Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases.γ-干扰素表达细胞是炎症性肠病中白细胞介素-21 的主要来源。
Inflamm Bowel Dis. 2010 Aug;16(8):1332-9. doi: 10.1002/ibd.21238.
7
Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease.炎症性肠病中白细胞介素17和干扰素γ产生的差异调节
Gut. 2009 Dec;58(12):1629-36. doi: 10.1136/gut.2009.182170. Epub 2009 Sep 8.
8
Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study.FONTOLIZUMAB 在中重度克罗恩病中的应用:一项 2 期、随机、双盲、安慰剂对照、多剂量研究。
Inflamm Bowel Dis. 2010 Feb;16(2):233-42. doi: 10.1002/ibd.21038.
9
Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12.人类树突状细胞通过白细胞介素-12诱导产生白细胞介素-21的滤泡辅助样T细胞分化。
Immunity. 2009 Jul 17;31(1):158-69. doi: 10.1016/j.immuni.2009.04.016.
10
Infliximab prevents Crohn's disease recurrence after ileal resection.英夫利昔单抗可预防回肠切除术后克罗恩病复发。
Gastroenterology. 2009 Feb;136(2):441-50.e1; quiz 716. doi: 10.1053/j.gastro.2008.10.051. Epub 2008 Oct 31.